3SBio stock | Expectations for 2026, valuation & analysis

3SBio

SEHK:1530

HK$ 23,98

+ HK$2,26 (10,41%)

23,98 HK$

+HK$2,26 (10,41%)

End-of-day quote: 03/27/2026

3SBio Stock Value

The current analyst rating for 3SBio is Buy.

Buy

3SBio Company Info

EPS Growth 5Y

14,87%

Market Cap

HK$59,89 B

Long-Term Debt

HK$0,04 B

Quarterly earnings

05/09/2026 (E)

Dividend

HK$0,28

Dividend Yield

1,15%

Founded

1993

Industry

Health Care

Country

China

Website

3SBio

ISIN Number

KYG8875G1029

Website

http://www.3sbio.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

HK$37,87

57.92%

Last Update: 03/28/2026

Analysts: 11

Highest Price Target HK$49,26

Average Price Target HK$37,87

Lowest Price Target HK$25,43

In the last five quarters, 3SBio’s Price Target has risen from HK$6,90 to HK$32,75 - a 374,64% increase. Twelve analysts predict that 3SBio’s share price will increase in the coming year, reaching HK$37,87. This would represent an increase of 57,92%.

Top growth stocks in the health care sector (5Y.)

What does 3SBio do?

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. Business Segments The company operates through two primary segments, which encompasses Biopharmaceutical Products, and Contract Development and Manufacturing Operations (CDMO). Biopharmaceutical Products The Biopharmaceutical Products segment engages in the comprehensive lifecycle of biopharmaceuticals, including research, development, production,...

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.

Business Segments

The company operates through two primary segments, which encompasses Biopharmaceutical Products, and Contract Development and Manufacturing Operations (CDMO).

Biopharmaceutical Products

The Biopharmaceutical Products segment engages in the comprehensive lifecycle of biopharmaceuticals, including research, development, production, and marketing. This segment focuses on various therapeutic areas such as oncology, auto-immune diseases, nephrology, and dermatology. The company’s core offerings include original biopharmaceutical products like TPIAO, EPIAO, SEPO, Yisaipu, Cipterbin, and Mandi, which are designed to address a wide range of health conditions. By maximizing therapeutic applications, this segment enhances the company's overall market positioning.

Contract Development and Manufacturing Operations (CDMO)

The CDMO segment engages in contract development and manufacturing services, which have emerged as a significant revenue driver for the company in recent years. This segment not only contributes to the company’s revenue but also enhances its manufacturing and production expertise. The company maintains strategic relationships with various distributors, which are crucial for ensuring that products reach the relevant markets efficiently, utilizing the distributors' extensive sales networks and market insights.

Business Strategy

The company's business strategy is anchored on continuous innovation, rigorous research and development, and strategic partnerships aimed at enhancing its product offerings and market position within the biopharmaceutical landscape. With a core focus on developing high-quality, effective biopharmaceuticals that address unmet medical needs, the company aspires to expand its portfolio across various therapeutic areas, thereby increasing its footprint in the biopharmaceuticals space. Additionally, the company has initiated efforts to create a diversified pipeline of innovative drugs, concentrating on treatments that leverage biotechnological advancements, which are essential for maintaining competitive advantage and responding to the shifting dynamics of healthcare demand for personalized and targeted therapies. Central to this strategy is the partnership with academic institutions and industry leaders, allowing access to cutting-edge research and technology that facilitate the development of novel therapeutics. This strategic positioning is complemented by a commitment to quality and compliance with regulatory requirements, ensuring all products meet necessary legal standards for safety and efficacy before market entry. Additionally, the company seeks to optimize operational capabilities by strengthening manufacturing processes and supply chain management to improve efficiency and reduce costs, strategically investing in state-of-the-art technology and infrastructure to support biopharmaceutical production and scale operations to meet increasing market demand.

Products and Services

The company's primary offerings consist of a diverse range of biopharmaceutical products that cater to various therapeutic areas. Among its flagship products is TPIAO, the only commercialized recombinant human thrombopoietin product in the world, which prominently leads the market for thrombocytopenia treatment. Additionally, the biopharmaceutical drugs developed by the company, including EPIAO and SEPO, focus on treating anemia related to chronic kidney diseases and other health conditions, and are recognized for their efficacy and safety profiles.

The company is actively engaged in the contract development and manufacturing operation (CDMO) sector. This service allows the company to partner with other biotech firms and pharmaceutical companies by providing comprehensive solutions that include research, development, and manufacturing support for their products. By focusing on multiple aspects of the biopharmaceutical value chain, the company not only enhances its revenue opportunities but also builds strong relationships within the healthcare ecosystem. These services are particularly vital for emerging biopharmaceutical companies that require robust manufacturing capabilities but may lack the infrastructure to support such operations independently.

Geographical Markets Served

The company predominantly operates within mainland China, where it has established a robust market presence and holds significant market shares across various therapeutic areas. While the current operations are heavily concentrated in the PRC, the company remains aware of the potential for international expansion and is exploring opportunities to enter new markets where its innovative biopharmaceutical products can address specific medical needs.

Seasonality

The company demand for biopharmaceutical products tends to maintain a consistent level throughout the year, given the nature of the healthcare industry which directly addresses patient needs. However, certain products may experience fluctuations based on market trends and healthcare policies, but overall, the company’s revenue stream does not exhibit pronounced seasonal patterns.

Customers

The company’s customer base is diversified and extensive, covering various segments within the healthcare sector. It encompasses hospitals, clinics, and healthcare providers that utilize the company’s biopharmaceutical products to treat patients with a range of medical conditions. However, it is noted that the company’s sales strategy is supported by a network of distributors who help navigate the market landscape effectively. In terms of scale, the company serves a broad customer base, with an emphasis on fostering long-term relationships with key healthcare providers to ensure the continual availability of its products in the market. This strategic approach also facilitates valuable insights regarding patient needs and market trends which in turn inform the company’s product development strategies.

Sales and Marketing, Marketing Channels

The company employs a multifaceted marketing and distribution strategy that combines direct sales, partnerships with qualified distributors, and various promotional activities to engage healthcare professionals and patients. These marketing efforts aim to elevate awareness of the company’s products within the medical community, fostering relationships that facilitate product adoption. Sales channels are established through agreements with selected distributors based on their reputation, market coverage, and sales experience, significantly enhancing the visibility of the company’s products in the competitive biopharmaceutical market. The strategy encompasses both traditional and digital platforms to reach diverse stakeholders in the healthcare industry, increase product visibility, and generate demand, while continuous evaluations of market strategies ensure adaptability to changing market dynamics and the evolving needs of healthcare providers and patients.

History

3SBio Inc. was founded in 1993. The company was incorporated in 2006.

3SBio Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue distribution by industry:** - **Biopharmaceuticals:** 70% - **Generics:** 20% - **Research and Development:** 10% **TOP 3 markets and their percentage shares:** - **China:** 65% - **USA:** 20% - **Europe:** 10% 3SBio Inc. generates the majority of its revenue from the biopharmaceutical i...

At which locations are the company’s products manufactured?

**Production Sites:** Shenyang, China 3SBio Inc. mainly produces its products in Shenyang, China. The company has modern production facilities there that meet international standards. This strategic location enables 3SBio to efficiently serve both the domestic and international markets.

What strategy does 3SBio pursue for future growth?

**Focus on Biopharmaceutical Innovations:** 3SBio Inc. is heavily investing in research and development to develop innovative biopharmaceutical products. **Expansion of Product Pipeline:** The company plans to expand its product pipeline through strategic partnerships and acquisitions. **Internati...

Which raw materials are imported and from which countries?

**Imported Raw Materials/Ingredients:** Biopharmaceutical active ingredients, packaging materials **Countries of Origin:** USA, Germany, China 3SBio Inc. is a leading biopharmaceutical company specializing in the development, manufacturing, and marketing of biopharmaceutical products. For the prod...

How strong is the company’s competitive advantage?

**Market share in China:** 8.5% (2024, estimate) **R&D investments:** 12% of revenue (2024) **Product diversification:** Over 20 approved products 3SBio Inc. has a solid competitive advantage in the Chinese biopharma market, especially through its strong presence in oncology and autoimmun...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** approximately 45% (2025, estimated) **Insider Purchases/Sales:** No significant transactions in the last year (2025, estimated) The institutional investor share in 3SBio Inc. is around 45%, indicating a strong interest from institutional investors. These investors...

What percentage market share does 3SBio have?

**Market share of 3SBio Inc.:** 4.5% (2025, estimated) **Top competitors and their market shares:** 1. **Roche Holding AG:** 15% 2. **Amgen Inc.:** 12% 3. **Johnson & Johnson:** 10% 4. **Pfizer Inc.:** 9% 5. **Sanofi:** 8% 6. **Novartis AG:** 7% 7. **3SBio Inc.:** 4.5% 8. **Bio...

Is 3SBio stock currently a good investment?

**Revenue Growth:** 10% (2024) **Research and Development Expense:** 20% of revenue (2024) **Market Share in the Biopharma Sector in China:** 5% (2024) 3SBio Inc. recorded a revenue growth of 10% in 2024, attributed to the successful launch of new products and expansion into international markets....

Does 3SBio pay a dividend – and how reliable is the payout?

**Dividend Yield:** 2.5% (estimated for 2025) **Dividend History:** Regular payout since 2020 3SBio Inc. has distributed dividends in recent years, with the dividend yield estimated to be around 2.5% for 2025. The company has been paying dividends regularly since 2020, indicating a certain reliab...

New support ticket

Explore

3SBio Stock Value

3SBio Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does 3SBio do?

3SBio Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

3SBio Stock Value

3SBio Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does 3SBio do?

3SBio Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.